BR112016007563B1 - Tiazolopirimidinonas, seus usos, e composição farmacêutica - Google Patents

Tiazolopirimidinonas, seus usos, e composição farmacêutica Download PDF

Info

Publication number
BR112016007563B1
BR112016007563B1 BR112016007563-3A BR112016007563A BR112016007563B1 BR 112016007563 B1 BR112016007563 B1 BR 112016007563B1 BR 112016007563 A BR112016007563 A BR 112016007563A BR 112016007563 B1 BR112016007563 B1 BR 112016007563B1
Authority
BR
Brazil
Prior art keywords
methyl
thiazolo
pyrimidin
trifluoromethyl
oxo
Prior art date
Application number
BR112016007563-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016007563A2 (pt
Inventor
Jiang Yu
Guosheng Wu
Po-Wai Yuen
Elisia Villemure
Jacob Schwarz
Cuong Ly
Benjamin Sellers
Matthew Volgraf
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112016007563A2 publication Critical patent/BR112016007563A2/pt
Publication of BR112016007563B1 publication Critical patent/BR112016007563B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112016007563-3A 2013-10-11 2014-10-08 Tiazolopirimidinonas, seus usos, e composição farmacêutica BR112016007563B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2013085031 2013-10-11
CNPCT/CN2013/085031 2013-10-11
CN2014085959 2014-09-05
CNPCT/CN2014/085959 2014-09-05
PCT/EP2014/071522 WO2015052226A1 (en) 2013-10-11 2014-10-08 Thiazolopyrimidinones as modulators of nmda receptor activity

Publications (2)

Publication Number Publication Date
BR112016007563A2 BR112016007563A2 (pt) 2020-04-28
BR112016007563B1 true BR112016007563B1 (pt) 2022-12-20

Family

ID=51688060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007563-3A BR112016007563B1 (pt) 2013-10-11 2014-10-08 Tiazolopirimidinonas, seus usos, e composição farmacêutica

Country Status (19)

Country Link
US (2) US9988400B2 (https=)
EP (2) EP3415519A1 (https=)
JP (2) JP6419800B2 (https=)
KR (1) KR102361108B1 (https=)
CN (2) CN105612162B (https=)
BR (1) BR112016007563B1 (https=)
CA (1) CA2926830C (https=)
DK (1) DK3055315T3 (https=)
ES (1) ES2690355T3 (https=)
HR (1) HRP20181596T1 (https=)
HU (1) HUE040651T2 (https=)
LT (1) LT3055315T (https=)
MX (1) MX2016004540A (https=)
PL (1) PL3055315T3 (https=)
PT (1) PT3055315T (https=)
RS (1) RS58047B1 (https=)
RU (1) RU2703273C2 (https=)
SI (1) SI3055315T1 (https=)
WO (1) WO2015052226A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283487B1 (en) * 2015-04-15 2019-10-16 H. Hoffnabb-La Roche Ag Pyridopyrimidinones and their use as nmda receptor modulators
SMT202000534T1 (it) 2015-12-09 2020-11-10 Cadent Therapeutics Inc Modulatori eteroaromatici del recettore nmda e loro usi
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
WO2017109709A2 (en) 2015-12-22 2017-06-29 Novartis Ag A high-throughput assay method for identifying allosteric nmda receptor modulators
ES2975336T3 (es) * 2016-12-22 2024-07-04 Novartis Ag Moduladores del receptor NMDA y usos de los mismos
BR112021001967A2 (pt) 2018-08-03 2021-04-27 Cadent Therapeutics, Inc. moduladores de receptor nmda heteroaromáticos e usos dos mesmos
CN111840296B (zh) * 2020-07-22 2021-05-04 华中农业大学 一种5H-噻唑并[3,2-a]嘧啶-5-酮类化合物在制备单胺氧化酶抑制剂中的用途
CN112094267B (zh) * 2020-08-14 2025-06-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 1-苯基-吡咯并异喹啉-3-酮类化合物及其制备方法和应用
EP4032896A1 (en) * 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
US20250073242A1 (en) * 2021-07-30 2025-03-06 The Regents Of The University Of California Slc26a3 inhibitors and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888983A (en) * 1970-08-14 1975-06-10 Seperic Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
EP0891978B1 (en) 1997-07-18 2002-03-20 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2007006175A1 (en) 2005-07-11 2007-01-18 Zte Corporation Method for implementing channel shared ring protection supported easy failure prevention
NL2000397C2 (nl) * 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
JP6130061B2 (ja) 2013-06-19 2017-05-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft インドリン−2−オン又はピロロ−ピリジン/ピリミジン−2−オン誘導体
EP3283487B1 (en) 2015-04-15 2019-10-16 H. Hoffnabb-La Roche Ag Pyridopyrimidinones and their use as nmda receptor modulators

Also Published As

Publication number Publication date
SI3055315T1 (sl) 2018-11-30
RU2016115487A3 (https=) 2018-06-21
US20160222033A1 (en) 2016-08-04
BR112016007563A2 (pt) 2020-04-28
ES2690355T3 (es) 2018-11-20
CN108929336A (zh) 2018-12-04
RU2703273C2 (ru) 2019-10-16
CN105612162B (zh) 2018-08-21
US20180244694A1 (en) 2018-08-30
RS58047B1 (sr) 2019-02-28
CA2926830A1 (en) 2015-04-16
MX2016004540A (es) 2016-07-21
RU2016115487A (ru) 2017-11-16
HUE040651T2 (hu) 2019-03-28
CA2926830C (en) 2023-08-01
US10647731B2 (en) 2020-05-12
CN105612162A (zh) 2016-05-25
KR102361108B1 (ko) 2022-02-10
WO2015052226A1 (en) 2015-04-16
PL3055315T3 (pl) 2018-12-31
LT3055315T (lt) 2018-10-25
JP6419800B2 (ja) 2018-11-07
JP2019023217A (ja) 2019-02-14
EP3055315B1 (en) 2018-07-25
US9988400B2 (en) 2018-06-05
PT3055315T (pt) 2018-10-25
JP2016532669A (ja) 2016-10-20
KR20160068898A (ko) 2016-06-15
EP3055315A1 (en) 2016-08-17
HRP20181596T1 (hr) 2018-12-14
HK1220202A1 (zh) 2017-04-28
EP3415519A1 (en) 2018-12-19
DK3055315T3 (en) 2018-10-22

Similar Documents

Publication Publication Date Title
RU2703273C2 (ru) Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda
JP7299837B2 (ja) 化合物、組成物、および使用方法
CN112638917B (zh) 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
JP2024539228A (ja) 含窒素四環式化合物、その調製方法及びその医薬的使用
JP6526352B2 (ja) ニコチン性アセチルコリン受容体のアロステリック調節剤
ES2952332T3 (es) Compuestos espirocíclicos y sus métodos de preparación y uso
BR122019020716B1 (pt) heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende
EP4223759B1 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
EP3283487B1 (en) Pyridopyrimidinones and their use as nmda receptor modulators
AU2013307239A1 (en) Diazepinone derivatives useful for the treatment of fragile X syndrome, Parkinsons or Reflux Disease
HK1220202B (zh) 作为nmda受体活性的调节剂的噻唑并嘧啶酮类
KR20260019509A (ko) Gpr68 조절 활성을 갖는 이환식 헤테로아릴아미드
TW202604527A (zh) 一種含氮雜環類化合物、其製備方法及其應用
HK40046602A (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
BR122025015788A2 (pt) Compostos de aminopirazina diol, seus usos como inibidores de pi3k- gama e composição farmacêutica dos mesmos
EA035585B1 (ru) Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2558 DE 14/01/2020 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2014, OBSERVADAS AS CONDICOES LEGAIS